Last reviewed · How we verify
"Basel" Cocktail
At a glance
| Generic name | "Basel" Cocktail |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- In Vivo Determination of Cytochrome P450 Activities in Patients With Liver Cirrhosis (NA)
- Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects (PHASE1)
- Pharmacokinetics of the Basel Phenotyping Cocktail Combination Capsule (NA)
- Pharmacokinetic Study to Characterize Phenotyping Metrics of the "Basel" Cocktail After CYP Induction or Inhibition (PHASE1)
- Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- "Basel" Cocktail CI brief — competitive landscape report
- "Basel" Cocktail updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI